Opendata, web and dolomites

3DLT SIGNED

3D Living Tissues

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 3DLT project word cloud

Explore the words cloud of the 3DLT project. It provides you a very rough idea of what is the project "3DLT" about.

estimating    care    commercialization    trials    lymph    tests    cutting    respect    oncological    asap    jan    strategy    company    2bln    efficient    expenditures    clinical    cancer    satisfy    corresponding    compartmentalization    asymp    2019    revenue    preclinical    share    molecules    yearn    pharmacological    once    immuneonco    tissues    composition    develops    forecast    structure    1st    rate    acquire    uncomplete    time    unreliable    3d    mln    safety    contrary    equal    bioprinting    proprietary    requests    performed    spends    market    40mln    data    human    undertaking    cosmetic    prometheus    96    deeply    living    3dln    companies    entire    remaining    animal    customers    economic    connect    business    alive    cells       price    drugs    ones    ematik    strictly    times    commercial    edge    excluding    printed    cell    printing    reduce    predictive    medicine    framework    node    immunotherapies    resolution    building    markets    feasibility    expenditure    wounds    pharma    regenerative    drug    opportunity    vitro    connecting    ink    industrial    fails    5bln    ip   

Project "3DLT" data sheet

The following table provides information about the project.

Coordinator
PROMETHEUS S.R.L. 

Organization address
address: VIA TRENTO 30
city: PARMA
postcode: 43122
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.prometheus3d.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PROMETHEUS S.R.L. IT (PARMA) coordinator 50˙000.00

Map

 Project objective

Prometheus S.r.l. develops and markets 3D human like tissues for regenerative medicine and pharmacological tests. A proprietary 3D Bioprinting Technology enables Prometheus to make use of human living cells as ink, to building up 3D tissues equal for structure and features to the human ones. The human living cells are printed by a strictly controlled process with high resolution, remaining alive during the entire printing process and for a long time beyond. The cutting edge new tissues satisfy the requests of pharma/cosmetic companies to reduce R&D expenditures and times for new products commercialization. Prometheus will go-to-market in Jan 2019 with its 1st product: Ematik, for wounds care. In this framework, Prometheus is undertaking a new business opportunity: a 3D Lymph Node (3DLN) for the testing of new immunotherapies against cancer. The 96% of oncological drugs efficient/safety in preclinical tests, fails human clinical trials, with a 2,5Bln$ expenditure/drug. This high failure rate is due to in vitro tests performed with current unreliable tissues: uncomplete, with different cell composition and compartmentalization respect to the corresponding human once. Contrary, Prometheus’ 3D Lymph Node is equal to the human one for composition, structure and functionality, providing more predictive data. Each company tests 80 new molecules/year and spends ≈4 Mln$ for in vitro tests, excluding animal testing (≈4 Mln$). Market of products for immuneonco testing is estimated in 2Bln€. According to key topics, all potential EU customers yearn to find on the market, asap, at any price, a 3D Lymph Node as the one of Prometheus, whose features allow to rapidly acquire a 4% EU market share in 5 years (40Mln€). During the feasibility study we will assess 3DLN project economic feasibility, we will connect with potential customers, estimating deeply market share, defining a revenue forecast, connecting with industrial and commercial partners, define also an IP strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "3DLT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "3DLT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

EVERCAM (2020)

Intelligent Vision System for Improved Communication and Higher Productivity in Construction

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More